BCYC BICYCLE THERAPEUTICS PLC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1761612 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY194.7%
TTM net income YoY43.4%
TTM EPS YoY43.9%
Revenue 3-yr CAGR49.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-189.4%
Net margin-169.8%
FCF margin-211.9%
EBITDA margin-183.8%
Returns
ROE-25.2%
ROA-21.3%
ROIC (approx.)-4,542.9%
Asset turnover0.13x
Leverage & solvency
Liabilities / assets10.9%
Debt / equity0.00x
Current ratio12.09x
Interest coverage-815.60x
Cash quality & payout
Operating cash flow / net income1.24x
Accruals ratio5.0%
Payout ratio—
Capex / revenue2.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $34.06M | $629,000 | $887,000 | $47.95M | $11.73M | $2.92M | $9.98M | $3.71M |
| R&D expense | $33.42M | $41.16M | $48.90M | $51.77M | $58.43M | $71.03M | $59.06M | $49.78M |
| SG&A expense | $14.11M | $14.03M | $17.47M | $20.89M | $18.86M | $18.49M | $21.12M | $21.59M |
| Operating income | -$13.48M | -$54.56M | -$65.48M | -$24.71M | -$65.55M | -$86.60M | -$70.20M | -$67.66M |
| Interest expense | $45,000 | $44,000 | $48,000 | $57,000 | $44,000 | $54,000 | $51,000 | $52,000 |
| Pretax income | -$9.31M | -$50.24M | -$60.65M | -$18.89M | -$58.90M | -$79.18M | -$61.84M | -$52.94M |
| Income tax | $1.17M | $90,000 | $172,000 | $1.26M | $205,000 | -$231,000 | -$1.09M | -$1.08M |
| Net income | -$10.48M | -$50.33M | -$60.83M | -$20.15M | -$59.10M | -$78.95M | -$60.75M | -$51.85M |
| EBITDA | -$12.38M | -$53.46M | -$64.35M | -$23.37M | -$63.75M | -$84.90M | -$68.57M | -$65.96M |
| EPS (basic) | -0.15 | -0.72 | -0.87 | — | -0.85 | -1.14 | -0.88 | — |
| EPS (diluted) | -0.15 | -0.72 | -0.87 | — | -0.85 | -1.14 | -0.88 | — |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 69.98M | 69.80M | 69.68M | — | 69.30M | 69.25M | 69.20M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $469.93M | $510.05M | $559.47M | $628.11M | $648.33M | $721.45M | $792.97M | $880.07M |
| Receivables | — | — | — | $0 | — | — | $136,000 | $0 |
| Current assets | $537.56M | $575.24M | $619.13M | $682.88M | $738.82M | $804.26M | $856.09M | $928.61M |
| PP&E, net | $4.21M | $4.70M | $5.73M | $6.02M | $6.86M | $8.31M | $8.74M | $9.52M |
| Total assets | $567.18M | $606.58M | $652.40M | $717.60M | $763.95M | $832.18M | $883.89M | $956.87M |
| Current liabilities | $44.46M | $47.63M | $48.89M | $56.98M | $69.28M | $77.42M | $57.62M | $67.23M |
| Total liabilities | $61.90M | $96.32M | $98.08M | $107.62M | $145.47M | $163.27M | $143.56M | $163.81M |
| Shareholders' equity | $505.28M | $510.25M | $554.32M | $609.98M | $618.48M | $668.91M | $740.33M | $793.06M |
| Shares outstanding | 69.99M | 69.81M | 69.71M | 69.37M | 69.31M | 69.25M | 69.20M | 69.06M |
| Cash flow statement | ||||||||
| Operating cash flow | -$40.30M | -$49.61M | -$65.92M | -$19.35M | -$71.17M | -$72.79M | -$86.37M | -$9.40M |
| Capital expenditure | $305,000 | $265,000 | $713,000 | $574,000 | $674,000 | $498,000 | $604,000 | $368,000 |
| Free cash flow | -$40.61M | -$49.87M | -$66.64M | -$19.92M | -$71.85M | -$73.28M | -$86.97M | -$9.76M |
| Investing cash flow | -$305,000 | -$265,000 | -$713,000 | -$574,000 | -$674,000 | -$498,000 | -$604,000 | -$368,000 |
| Financing cash flow | -$31,000 | -$50,000 | -$54,000 | -$15,000 | -$30,000 | -$45,000 | -$41,000 | $203,000 |
| Depreciation & amortization | $1.10M | $1.10M | $1.13M | $1.34M | $1.80M | $1.70M | $1.63M | $1.70M |
| Stock-based compensation | $5.42M | $6.40M | $6.93M | $11.65M | $8.77M | $9.44M | $9.61M | $10.33M |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.